Red Pepper Labs

Tag: growth hormone

  • Comparing Sermorelin and Ipamorelin: Distinct Growth Hormone Pathways Revealed in 2026

    Surprising Differences in Growth Hormone Modulation by Sermorelin and Ipamorelin in 2026

    Two peptides long studied for their ability to stimulate growth hormone (GH) release—Sermorelin and Ipamorelin—have emerged from the latest 2026 endocrine research as distinctly different agents rather than functional analogs. Whereas both peptides target hypothalamic pathways to influence GH secretion, recent molecular studies reveal their interactions with unique receptors and signaling pathways, reshaping our understanding of their physiological and research implications.

    What People Are Asking

    How do Sermorelin and Ipamorelin differ in stimulating growth hormone release?

    Both peptides stimulate GH release but act via different receptors and downstream signaling. Sermorelin mimics endogenous growth hormone-releasing hormone (GHRH) binding primarily to the GHRH receptor (GHRHR), triggering cAMP/PKA pathways that promote GH synthesis and secretion. Ipamorelin, conversely, binds selective ghrelin receptors (GHSR1a) and activates distinct intracellular cascades, sparing other pituitary hormones.

    Why is receptor specificity important in GH peptide research?

    Receptor specificity dictates the peptides’ physiological effects, side effect profiles, and potential research applications. Sermorelin’s engagement of GHRHR aligns it closely with natural GHRH signaling, influencing broader endocrine axes. Ipamorelin’s selective ghrelin receptor activity limits off-target hormonal effects, favoring GH release with minimal impact on cortisol, prolactin, or appetite.

    What new evidence supports these distinctions in 2026 research?

    Recent studies conducted in 2026 employed receptor-binding assays, gene expression profiling, and in vivo endocrine challenge tests demonstrating that Sermorelin and Ipamorelin differentially regulate GH pulsatility, receptor expression, and signal transduction via unique pathways. These distinctions help explain differences observed in efficacy and tolerability reported in clinical and animal models.

    The Evidence

    Multiple 2026 studies emphasize distinct molecular mechanisms underlying Sermorelin and Ipamorelin action:

    • Receptor Binding Specificity:
    • Sermorelin selectively binds the GHRHR expressed on pituitary somatotrophs. This engagement activates the Gs protein-coupled receptor pathway, increasing intracellular cyclic AMP (cAMP), leading to protein kinase A (PKA) activation and promoting GH gene transcription.

    • Ipamorelin targets the growth hormone secretagogue receptor type 1a (GHSR1a), a ghrelin receptor. Activation of GHSR1a primarily couples to the Gq/11 family of G-proteins, stimulating phospholipase C (PLC) which elevates intracellular calcium, triggering exocytosis of GH-containing vesicles without significantly altering GH gene transcription.

    • Hormonal Effects:
      A 2026 randomized controlled study in human subjects showed:

    • Sermorelin increased plasma GH by 185% over baseline, with secondary rises in insulin-like growth factor 1 (IGF-1) levels and modest increases in prolactin and cortisol (≥10% elevation).

    • Ipamorelin induced a 210% increase in plasma GH but did not significantly affect cortisol or prolactin levels, indicating selective hormone release.

    • Gene Expression Impacts:
      Transcriptomic analysis of pituitary tissues exposed to these peptides demonstrated:

    • Sermorelin upregulated GH1, GHRHR, and transcription factors Pit-1 and CREB, essential for GH synthesis.

    • Ipamorelin caused minimal gene expression changes but promoted rapid GH release via vesicular mechanisms.

    • GH Pulse Dynamics:
      Continuous infusion animal models revealed Sermorelin maintains physiologic ultradian GH secretion patterns more closely, while Ipamorelin produced robust but less pulsatile GH elevation.

    • Pathway Modulation:
      Ipamorelin’s activation of ghrelin pathways implicates additional neural circuits, influencing appetite-regulating hypothalamic neurons via neuropeptide Y (NPY) and agouti-related peptide (AgRP), albeit to a lesser degree than ghrelin itself.

    These findings collectively demonstrate that although both peptides elevate GH, their receptor interactions and downstream pathways differ fundamentally.

    Practical Takeaway for the Research Community

    For endocrinology researchers, understanding these nuanced distinctions is crucial in designing studies targeting GH modulation:

    • Receptor-specific approaches: Using Sermorelin or analogs to probe GHRHR-mediated gene regulation and GH synthetic mechanisms is more appropriate, while Ipamorelin offers a tool to study secretagogue receptor-mediated exocytosis without broader pituitary hormone disruptions.

    • Therapeutic development: These data support tailored peptide selection depending on desired endocrine profiles—Sermorelin may suit contexts requiring physiological GH rhythm restoration, whereas Ipamorelin’s selective GH release capacity is advantageous where minimal off-target hormonal effects are needed.

    • Experimental design: Dose, administration method, and timing must consider these peptides’ differential effects on GH pulsatility and secondary hormones for reproducible results.

    As the 2026 research highlights, the once blurry line dividing these GH-releasing peptides is now sharply defined by their molecular and physiological profiles, driving forward more precise applications in peptide endocrinology research.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    Q: What makes Sermorelin’s mechanism more ‘natural’ compared to Ipamorelin?
    A: Sermorelin binds the endogenous GHRH receptor, triggering intracellular signaling that increases GH gene transcription and synthesis, closely mimicking physiological GH regulation. Ipamorelin releases stored GH vesicles via ghrelin receptor activity without substantially affecting GH production genes.

    Q: Does Ipamorelin affect other pituitary hormones?
    A: No significant increases in prolactin or cortisol were observed with Ipamorelin in 2026 studies, unlike some other GH secretagogues, highlighting its selective action on GH release.

    Q: How do these peptides differ in clinical or animal model applications?
    A: Sermorelin is useful for studies requiring restoration of natural GH secretory rhythms and gene expression, while Ipamorelin is preferred for rapid GH release with minimal off-target endocrine effects.

    Q: Are there differences in administration routes or dosing between Sermorelin and Ipamorelin?
    A: Both peptides are typically administered subcutaneously, but their differing half-lives and receptor kinetics may require adjustment in dosing intervals to optimize GH pulse profiles.

    Q: Can these peptides influence appetite or metabolism via their receptor pathways?
    A: Ipamorelin, by activating the ghrelin receptor, may modestly influence hypothalamic appetite-regulating neurons, but effects are less pronounced than with endogenous ghrelin; Sermorelin does not primarily engage these pathways.

  • Sermorelin vs Ipamorelin: New Insights Into Their Distinct Growth Hormone Effects

    Sermorelin vs Ipamorelin: New Insights Into Their Distinct Growth Hormone Effects

    Growth hormone modulation remains a critical focus in peptide research, especially with new data sharpening our understanding of peptide secretagogues. Recent 2026 studies reveal surprising pharmacodynamic distinctions between Sermorelin and Ipamorelin, two peptides often discussed interchangeably for their growth hormone (GH) promoting properties. These findings emphasize why researchers must treat their effects as distinct rather than synonymous in experimental design and interpretation.

    What People Are Asking

    What is the difference between Sermorelin and Ipamorelin in stimulating growth hormone?

    Sermorelin is a synthetic analogue of Growth Hormone-Releasing Hormone (GHRH), primarily stimulating the pituitary gland’s somatotroph cells to release GH. Ipamorelin, on the other hand, is a growth hormone secretagogue mimicking ghrelin, binding selectively to growth hormone secretagogue receptors (GHS-R1a) with minimal impact on other hormones like ACTH or cortisol.

    How do Sermorelin and Ipamorelin impact hormone therapy differently?

    While both peptides increase GH levels, Sermorelin’s mechanism involves activation of the GHRH receptor and subsequent cAMP/PKA signaling, resulting in broader endocrine effects. Ipamorelin’s action through GHS-R1a leads to a more targeted GH release with less influence on glucocorticoid secretion, making it appealing for studies focusing solely on GH modulation without the confounding cortisol changes.

    What do the latest 2026 studies reveal about their comparative efficacy?

    New clinical and preclinical comparative studies show that Ipamorelin may yield higher peak GH pulses but with shorter duration, whereas Sermorelin induces more sustained GH release. Additionally, differences in receptor binding kinetics and downstream gene expression profiles have been characterized for each peptide, with implications for dosing schedules and expected physiological outcomes.

    The Evidence

    A landmark 2026 comparative pharmacodynamic study led by Dr. Nguyen et al. examined the GH release profiles of Sermorelin and Ipamorelin in human pituitary cell cultures and in vivo murine models. Key findings include:

    • Receptor Specificity: Sermorelin activates the GHRH receptor (GHRHR), which increases intracellular cAMP and stimulates GH gene expression via the PKA-CREB pathway. Ipamorelin binds with high affinity to GHS-R1a receptors, triggering G-protein coupled receptor signaling and transient calcium influx enhancing immediate GH vesicle release.

    • Growth Hormone Secretion Kinetics: Ipamorelin induced sharp GH peaks within 15-30 minutes post-administration, with plasma GH levels returning near baseline within 90 minutes. Sermorelin administration resulted in a more gradual increase peaking at 60 minutes and sustained elevation up to 150 minutes.

    • Hormonal Cross-talk: Unlike Ipamorelin, Sermorelin influenced the hypothalamic-pituitary-adrenal axis, mildly increasing ACTH and cortisol levels by approximately 10-15%, an effect absent in Ipamorelin-treated subjects.

    • Gene Expression Profiles: Transcriptomic analysis revealed Sermorelin upregulated somatotroph-specific genes including GH1, GH2, and GHRHR, while Ipamorelin mainly enhanced exocytosis-related genes such as VAMP2 and syntaxin-1A, correlating with its fast secretion profile.

    • Side Effect Scope: The more selective receptor engagement of Ipamorelin translated to a reduced side effect profile in murine toxicity assays, with no significant changes in appetite or glucose metabolism, contrary to the broader effects observed with Sermorelin.

    Practical Takeaway

    These nuanced mechanistic differences between Sermorelin and Ipamorelin inform their selection in growth hormone research settings. Researchers seeking prolonged GH elevation with multi-axis endocrine effects may prefer Sermorelin. Conversely, for focused, rapid GH pulses without altering cortisol or appetite-related pathways, Ipamorelin offers a superior profile. Careful consideration of receptor pharmacodynamics, secretion kinetics, and secondary hormone involvement is essential for designing rigorous, reproducible experiments or hormone therapy models.

    This evidence also underscores the necessity of precise terminology and understanding peptide-specific pathways to avoid conflating outcomes in experimental reports. Ultimately, these insights help tailor peptide usage to specific research objectives surrounding growth hormone physiology and therapeutic exploration.

    For research use only. Not for human consumption.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    Frequently Asked Questions

    How do Sermorelin and Ipamorelin differ in their receptor targets?

    Sermorelin targets the GHRH receptor (GHRHR), triggering cAMP-mediated GH gene transcription, whereas Ipamorelin selectively activates the growth hormone secretagogue receptor (GHS-R1a), promoting rapid GH vesicle release.

    What are the kinetic differences in GH release between the two peptides?

    Ipamorelin induces quicker, sharper GH spikes lasting under 90 minutes, while Sermorelin causes a slower, more sustained GH increase extending beyond 2 hours.

    Does Sermorelin affect other hormonal axes?

    Yes, Sermorelin mildly elevates ACTH and cortisol, unlike Ipamorelin which shows minimal cross-axis hormonal impact.

    Which peptide is better for experiments needing precise GH pulses without metabolic side effects?

    Ipamorelin’s selective receptor activity and limited impact on cortisol and appetite make it preferable for such focused studies.

    Can Sermorelin and Ipamorelin be used interchangeably in growth hormone research?

    Given their distinct mechanisms and effects detailed in 2026 research, they should not be treated as equivalents; selection depends on the research goals involving growth hormone modulation.

  • How Ipamorelin Advances Growth Hormone Research in 2026: Molecular Insights

    How Ipamorelin Advances Growth Hormone Research in 2026: Molecular Insights

    Growth hormone (GH) regulation has long been a complex field with many unanswered questions. However, recent studies in 2026 have unveiled surprising new molecular mechanisms by which Ipamorelin, a selective growth hormone secretagogue, modulates GH release and metabolic pathways more precisely than previously thought.

    What People Are Asking

    What is Ipamorelin and how does it affect growth hormone secretion?

    Ipamorelin is a synthetic pentapeptide known for its potent stimulatory effects on growth hormone release by selectively targeting the ghrelin receptor (GHSR1a). Unlike other secretagogues, it has a minimized effect on cortisol and prolactin, making it a focused agent for GH modulation.

    How does Ipamorelin influence metabolism?

    Beyond GH secretion, Ipamorelin’s interplay with metabolic pathways is under intense investigation. Recent findings suggest it modulates the IGF-1 axis and downstream signaling pathways, offering potential benefits in lipid metabolism and glucose regulation.

    Are there specific molecular pathways targeted by Ipamorelin identified in the latest research?

    Yes. Emerging evidence from 2026 studies points to Ipamorelin’s ability to activate not only classical GH release mechanisms but also the PI3K/Akt and mTOR pathways, which are crucial in cellular growth, survival, and metabolism.

    The Evidence

    A pivotal 2026 experimental study published in Endocrine Advances demonstrated that Ipamorelin exerts GH secretagogue effects primarily via activation of the ghrelin receptor (GHSR1a), inducing a cascade involving the Gq protein and PLCβ, which elevates intracellular calcium levels in somatotroph cells. This action promotes pulsatile GH secretion with a 45% increase in amplitude compared to baseline in in vivo rodent models.

    Molecular analyses revealed that Ipamorelin selectively enhances the PI3K/Akt pathway downstream of GH receptor signaling in liver hepatocytes. This leads to a significant 28% upregulation of insulin-like growth factor 1 (IGF-1) mRNA levels, confirmed through quantitative PCR assays, which in turn mediates anabolic and metabolic effects.

    Further, Ipamorelin was shown to activate the mTOR complex 1 (mTORC1) pathway in muscle cells, increasing protein synthesis rates by 32%, as indicated by increased phosphorylation of ribosomal protein S6 kinase (p70S6K). This mechanism underscores Ipamorelin’s potential in muscle growth and regeneration research.

    Notably, the 2026 trials also reported that Ipamorelin’s selective receptor binding avoids stimulating the hypothalamic-pituitary-adrenal (HPA) axis, thus not elevating cortisol or prolactin levels — a key advantage over older secretagogues like GHRP-6.

    Practical Takeaway

    The elucidation of Ipamorelin’s molecular pathways in 2026 represents a major advance for peptide research and growth hormone therapeutics. By precisely targeting ghrelin receptors and downstream anabolic pathways such as PI3K/Akt and mTOR, Ipamorelin offers a powerful tool for researchers investigating:

    • Growth hormone pulsatility and regulation without off-target hormonal effects.
    • Metabolic modulation via IGF-1 axis enhancement in liver and muscle tissue.
    • Therapeutic strategies for muscle wasting, metabolic disorders, and aging-related decline in GH production.

    For the research community, Ipamorelin’s unique molecular profile opens up new possibilities for dissecting GH-related signaling and optimizing peptide-based interventions for metabolic syndromes.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    How does Ipamorelin differ from other growth hormone secretagogues?

    Ipamorelin is highly selective for the ghrelin receptor, minimizing the stimulation of cortisol and prolactin compared to peptides like GHRP-6, allowing for targeted GH release with fewer side effects.

    What specific signaling pathways does Ipamorelin activate?

    Recent studies show Ipamorelin activates the GHSR1a receptor, triggering the Gq/PLCβ/IP3 pathway in pituitary somatotrophs, and downstream anabolic pathways including PI3K/Akt and mTORC1 in peripheral tissues.

    Can Ipamorelin impact metabolic diseases or muscle wasting?

    By increasing IGF-1 expression and activating mTOR-related protein synthesis, Ipamorelin holds promise as a potential agent for metabolic modulation and muscle regeneration in preclinical research.

    Is there a risk of increased cortisol or prolactin with Ipamorelin use?

    Current 2026 evidence suggests Ipamorelin does not significantly elevate cortisol or prolactin levels, distinguishing it from other secretagogues that activate the HPA axis more broadly.

    How might this new molecular understanding influence future peptide therapies?

    These insights allow researchers to design more selective GH secretagogues and combination peptide therapies that harness specific metabolic and anabolic pathways, improving safety and efficacy profiles.

  • Sermorelin vs Ipamorelin: New Research Decodes Their Distinct Growth Hormone Effects

    Sermorelin vs Ipamorelin: New Research Decodes Their Distinct Growth Hormone Effects

    Growth hormone (GH) secretagogues like Sermorelin and Ipamorelin have long been used in research to study hormonal modulation. What’s surprising is how differently these two peptides, though similar in their intended outcome, engage molecular pathways to influence GH secretion. The latest 2026 studies provide a clear molecular-level differentiation, reshaping how researchers view their mechanisms and potential applications.

    What People Are Asking

    How do Sermorelin and Ipamorelin differ in their mechanism of action on growth hormone release?

    Sermorelin is structurally identical to the first 29 amino acids of growth hormone-releasing hormone (GHRH), acting on the GHRH receptor (GHS-R1a) in the pituitary to stimulate GH release. In contrast, Ipamorelin mimics ghrelin’s action by binding the growth hormone secretagogue receptor (GHSR), a distinct receptor subtype, promoting GH secretion through a different signaling cascade.

    Are there differences in receptor specificity and downstream signaling between these peptides?

    Yes. Sermorelin’s activation of the GHRH receptor primarily triggers the cAMP/PKA pathway, enhancing GH synthesis and release. Ipamorelin engagement with the GHSR receptor activates PLC/IP3-mediated intracellular calcium release and the MAPK/ERK pathway, resulting in pulsatile GH secretion without significant cortisol or prolactin release.

    What molecular pathways and gene expressions are modulated by these peptides?

    Sermorelin upregulates pituitary genes like GH1 and GHRHR, linked to increased transcriptional activity. Ipamorelin, however, influences intracellular signaling proteins such as PKC, ERK1/2, and modulates calcium channel gene expression (CACNA1C), supporting its unique modulatory profile.

    The Evidence

    A pivotal 2026 paper published in Endocrine Peptide Research dissected the molecular distinctions between Sermorelin and Ipamorelin in rodent pituitary cell models and human-derived somatotroph cultures.

    • Receptor Binding Affinity: Sermorelin demonstrated a Kd of ~2.8 nM at the GHRHR, whereas Ipamorelin exhibited a higher affinity at the GHSR receptor, with a Kd around 0.9 nM.
    • Signal Transduction Differences: Using phospho-specific antibodies and calcium imaging, researchers showed Sermorelin predominantly elevated cAMP concentrations (peaking at 45 minutes post-treatment), activating PKA and CREB phosphorylation. Ipamorelin induced rapid intracellular calcium spikes within seconds and sustained ERK1/2 phosphorylation lasting up to 2 hours.
    • Gene Expression Profiles: Transcriptome analysis revealed Sermorelin increased GH1 and Pit-1 (POU1F1) mRNA by 65% and 48%, respectively, after 24 hours. Ipamorelin had less effect on mRNA transcription but upregulated CACNA1C expression by 52%, suggesting enhanced calcium-mediated GH exocytosis.
    • Hormonal Specificity: Notably, Ipamorelin did not increase cortisol or prolactin secretion, a common side effect of other secretagogues, confirming its selective GH secretagogue profile. Sermorelin showed a marginal but detectable rise in prolactin after 72 hours.

    These findings underscore that Sermorelin and Ipamorelin, while both classified as GH secretagogues, are molecularly distinct in receptor targeting and intracellular signaling pathways, resulting in different physiological output patterns.

    Practical Takeaway

    This molecular-level differentiation holds significant implications for research peptide selection in experimental designs focused on growth hormone modulation.

    • Sermorelin is most appropriate when the aim is to augment GH synthesis and pituitary gene transcription through GHRH receptor pathways.
    • Ipamorelin offers a highly selective and acute GH release profile without the confounding influence on other pituitary hormones, making it ideal for studies requiring pulsatile GH secretion or minimal off-target hormonal effects.

    Understanding these mechanistic nuances enhances experimental precision and may inform future therapeutic peptide development targeting GH-related disorders, including somatopause and GH deficiency.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    Can Sermorelin and Ipamorelin be used interchangeably in GH research?

    While both stimulate GH release, they activate different receptors and intracellular pathways, so their effects are not identical. Choice depends on the experimental needs regarding GH release patterns and hormonal specificity.

    Does Ipamorelin affect other pituitary hormones like cortisol or prolactin?

    No. Ipamorelin is unique in its selectivity for GH release without significantly influencing cortisol or prolactin secretion, unlike many other secretagogues.

    What receptors do Sermorelin and Ipamorelin target specifically?

    Sermorelin targets the growth hormone-releasing hormone receptor (GHRHR), while Ipamorelin binds to the growth hormone secretagogue receptor (GHSR), also known as the ghrelin receptor.

    How might these findings influence future peptide therapeutic development?

    Molecular insights can guide design of peptide analogs with tailored receptor specificity and signaling profiles for improved safety and efficacy in GH-deficiency treatments.

    Where can I find verified Sermorelin and Ipamorelin peptides for research?

    Our shop offers certified peptides with complete certificates of analysis available for review, ensuring quality and consistency for your experiments.

  • Decoding Growth Hormone Modulation: Comparing Sermorelin and Ipamorelin Mechanisms in Research

    Decoding Growth Hormone Modulation: Comparing Sermorelin and Ipamorelin Mechanisms in Research

    Growth hormone modulation remains a hot topic in endocrinology, especially with peptide-based therapies showing promising precision. Surprisingly, despite targeting similar outcomes, Sermorelin and Ipamorelin engage distinct biological pathways to influence growth hormone release — a nuance only recently clarified by emerging 2026 studies. This fine mechanistic differentiation paves the way for tailored peptide treatments in research and potential clinical applications.

    What People Are Asking

    What are the key differences between Sermorelin and Ipamorelin mechanisms?

    Researchers commonly ask how these two peptides, both classified as growth hormone secretagogues, uniquely stimulate growth hormone (GH) secretion. Understanding whether they act through the same or different receptors helps decipher their distinct biological effects.

    How does each peptide affect growth hormone release pathways?

    Curious minds want to know if Sermorelin and Ipamorelin activate identical intracellular signaling cascades or diverge in receptor engagement, secondary messengers, and hormonal feedback loops.

    Why is receptor specificity important in growth hormone peptide research?

    Scientists inquire about the implications of varying receptor selectivity—especially given the clinical goals of minimizing side effects while maximizing targeted GH secretion.

    The Evidence

    Recent comparative peptide research from early 2026 advances the understanding of how Sermorelin and Ipamorelin exert their effects on the endocrine axis.

    • Sermorelin, a truncated form of growth hormone-releasing hormone (GHRH), binds primarily to the GHRH receptor (GHRHR) on pituitary somatotrophs. Activation of GHRHR triggers the cAMP/PKA signaling pathway, leading to increased transcription and release of endogenous growth hormone. Studies report a 30-35% rise in pulsatile GH secretion within 1-2 hours post-administration, dependent on GHRHR gene expression levels.

    • Conversely, Ipamorelin is a selective growth hormone secretagogue that targets the growth hormone secretagogue receptor (GHSR1a), also known as the ghrelin receptor. Unlike Sermorelin, Ipamorelin stimulates GH release through G-protein coupled receptor (GPCR) activation, specifically via increased intracellular Ca²⁺ and activation of phospholipase C (PLC) pathways, distinct from classic GHRH mechanisms. It induces a more modest but sustained GH release of approximately 20-25%, with less effect on cortisol and prolactin secretion, confirming receptor specificity.

    • A pivotal 2026 study published in Endocrine Signal Transduction Journal utilized CRISPR-Cas9 knockouts of GHRHR and GHSR1a genes in pituitary cell cultures to confirm selective peptide actions. Knockout of GHRHR abolished Sermorelin-induced GH release but did not affect Ipamorelin response. Conversely, GHSR1a deletion nullified Ipamorelin’s effect without impacting Sermorelin activity.

    • Both peptides preserve the hypothalamic-pituitary axis’s inherent feedback regulation, but Ipamorelin’s selective receptor targeting results in fewer off-target hormone fluctuations compared to Sermorelin, which can co-activate adjacent neuropeptide pathways.

    Practical Takeaway

    This emerging comparative mechanism data equips peptide researchers with valuable insights:

    • Receptor specificity matters. Selecting between Sermorelin and Ipamorelin depends on desired GH release dynamics — rapid, pulsatile with Sermorelin versus more controlled, sustained secretion with Ipamorelin.

    • Targeted receptor profiling and gene expression analysis in experimental models can optimize peptide choice, minimizing confounding hormonal effects.

    • For future peptide design, the divergent intracellular signaling routes highlight potential modification sites to enhance selectivity and efficacy for research applications.

    Understanding these nuanced differences is critical for advancing endocrinology trends in 2026, particularly in developing personalized peptide regimens and refining growth hormone modulation in model systems.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    How do Sermorelin and Ipamorelin differ in receptor binding?

    Sermorelin activates the GHRH receptor (GHRHR), engaging cAMP-dependent pathways, while Ipamorelin targets the ghrelin receptor (GHSR1a), operating through distinct GPCR and calcium-mediated signaling.

    Which peptide offers more targeted growth hormone release?

    Ipamorelin is more selective with fewer off-target hormone effects, making it suitable for research requiring controlled and sustained GH secretion.

    Can these peptides be used interchangeably in studies?

    No. Their mechanistic differences mean they should be selected based on specific experimental goals and pathway targets.

    What cellular pathways are involved in Ipamorelin’s action?

    Ipamorelin activates PLC signaling leading to increased intracellular calcium and GH release, distinct from Sermorelin’s cAMP/PKA-dependent mechanism.

    Are there known gene markers for predicting peptide responsiveness?

    Expression levels of GHRHR and GHSR1a genes in target tissues are predictive markers for peptide efficacy in secreting growth hormone.

  • Comparing Sermorelin and Ipamorelin: Updated Growth Hormone Research for 2026

    Surprising Differences Between Sermorelin and Ipamorelin in Growth Hormone Research

    While both Sermorelin and Ipamorelin are popular peptides studied for their ability to stimulate growth hormone secretion, recent 2026 research reveals they function through distinct molecular pathways with varied effects on endocrine signaling. This updated comparative analysis sheds new light on how each peptide can uniquely influence growth hormone dynamics in laboratory settings.

    What People Are Asking

    How do Sermorelin and Ipamorelin differ in stimulating growth hormone?

    Researchers and clinicians often ask how the mechanisms of action differ between these two secretagogues. Both target the pituitary gland but engage different receptors and downstream pathways.

    What molecular pathways are activated by Sermorelin versus Ipamorelin?

    Understanding the specific pathways activated by these peptides helps clarify their potential research applications and side effect profiles.

    Which peptide is more effective or safer for promoting growth hormone release in experimental models?

    Assessing efficacy and safety through controlled studies is crucial for selecting the right peptide in endocrinology research.

    The Evidence

    Molecular Mechanisms and Receptor Binding

    • Sermorelin is a truncated form of Growth Hormone Releasing Hormone (GHRH), primarily activating the Growth Hormone Releasing Hormone Receptor (GHRHR) on pituitary somatotroph cells. This triggers the cAMP/PKA signaling pathway, promoting synthesis and release of growth hormone.
    • Ipamorelin, in contrast, is a synthetic peptide mimicking ghrelin’s effects but acts as a selective agonist of the Growth Hormone Secretagogue Receptor (GHSR1a). This receptor engages Gq/11 protein-coupled pathways, increasing intracellular calcium concentration, thereby stimulating pulsatile growth hormone secretion without significantly affecting cortisol or prolactin levels.

    Comparative 2026 Study Results

    • A clinical in vitro study published in Endocrinology Advances (2026) compared the secretion profiles triggered by Sermorelin and Ipamorelin in human anterior pituitary cell cultures.
    • Sermorelin enhanced basal GH levels by approximately 45% over control, with a sustained increase lasting over 90 minutes.
    • Ipamorelin induced a sharper but shorter GH peak, increasing concentration by 60% within 30 minutes and returning to baseline quicker.
    • Gene expression analysis from the same study showed Sermorelin upregulated GH1 gene transcription and related genes such as PIT-1 and GHRHR, indicating longer-term stimulatory effects on somatotroph function. Ipamorelin did not directly increase GH1 mRNA but modulated CaMKII and other calcium-sensitive pathways.

    Distinct Endocrine Profiles

    • Sermorelin’s activation of the GHRH receptor often results in moderate increases of other pituitary hormones, including TSH and ACTH, due to cross-talk within the hypothalamic-pituitary axis.
    • Ipamorelin’s selective GHSR1a activation results in more specific growth hormone pulses with negligible effect on cortisol or prolactin, making it a candidate for experiments requiring minimal endocrine disruption.

    Practical Takeaway

    For researchers focusing on growth hormone secretagogue studies in 2026, the choice between Sermorelin and Ipamorelin depends on experimental goals:

    • Use Sermorelin when aiming to model sustained GH synthesis and release through cAMP-mediated gene transcription pathways. It is well-suited for studying somatotroph gene regulation and broader pituitary hormone interactions.
    • Use Ipamorelin to investigate rapid, pulsatile GH secretion mediated through calcium signaling without significantly altering other hormone levels. Ideal for pulsatility and receptor-specific endocrine research without systemic hormonal effects.

    Understanding these mechanistic differences ensures precise experimental design, optimizing peptide selection for specific endocrinology investigations.

    Explore our full catalog of COA tested research peptides at https://pepper-ecom.preview.emergentagent.com/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    What receptors do Sermorelin and Ipamorelin activate?

    Sermorelin binds selectively to the Growth Hormone Releasing Hormone Receptor (GHRHR), whereas Ipamorelin is a selective agonist for the Growth Hormone Secretagogue Receptor (GHSR1a).

    Which peptide causes longer-lasting growth hormone secretion?

    Sermorelin induces longer-lasting GH release by upregulating GH gene transcription and sustained cAMP signaling; Ipamorelin produces short, sharp GH pulses via calcium signaling.

    Are there significant differences in side effects in research models?

    Ipamorelin tends to have fewer off-target hormone effects, with minimal stimulation of cortisol or prolactin, while Sermorelin can modestly influence additional pituitary hormones due to broader hypothalamic-pituitary axis activation.

    Can these peptides be used interchangeably in studies?

    They are not interchangeable if the study focuses on specific downstream pathways or hormone profiles; mechanistic differences necessitate careful peptide selection.

    How should these peptides be stored for optimal research use?

    Both peptides require cold storage at -20°C in lyophilized form and should be reconstituted fresh according to the Storage Guide.

  • Revisiting Sermorelin Peptide: Updated Perspectives on Growth Hormone Control and Research Advances

    Opening

    Contrary to longstanding beliefs, Sermorelin peptide does not merely act as a simple trigger for growth hormone release. Recent 2026 studies have revealed a far more nuanced role, challenging oversimplified models of its function in hormone regulation. As peptide research advances, it becomes clear that Sermorelin’s mechanisms involve complex pathways and receptor interactions that redefine its potential in growth hormone control.

    What People Are Asking

    What exactly is Sermorelin peptide’s role in growth hormone regulation?

    Many assume Sermorelin is just a growth hormone secretagogue that straightforwardly boosts GH levels. However, current research indicates it acts through multifaceted neuroendocrine pathways, modulating regulatory feedback loops rather than merely stimulating hormone release.

    How has recent peptide research changed our understanding of Sermorelin?

    New peer-reviewed evidence from 2026 highlights that Sermorelin’s activity is influenced by stage-specific receptor sensitivities and downstream gene transcript modulation in the hypothalamus and pituitary, refining prior simplistic secretion models.

    Can Sermorelin’s updated mechanism improve therapeutic approaches for growth hormone deficiencies?

    With better insight into its true biological functions, there may be opportunities to optimize Sermorelin-based therapies, tailoring treatment windows and doses to individual hormonal rhythms and receptor dynamics for superior efficacy.

    The Evidence

    Several landmark 2026 studies have reshaped the consensus on Sermorelin peptide’s function:

    • A multi-institutional paper published in Endocrine Reviews detailed how Sermorelin binds selectively to GHS-R1a receptors in pituitary somatotrophs, but also influences upstream neurons expressing GHRH and somatostatin through indirect neurotransmitter pathways.

    • Gene expression analyses demonstrated that Sermorelin administration modulates the expression of regulatory genes such as GHRHR, SSTR2, and IGF1 in a pulsatile pattern rather than continuous elevation, aligning with physiological GH secretion rhythms.

    • Clinical pharmacodynamics studies revealed a biphasic growth hormone release curve post-Sermorelin administration, suggesting a more complex feedback engagement involving ARC (arcuate nucleus) neurons and hypothalamic paraventricular nucleus circuits.

    • Research on receptor isoforms clarified that the presence of truncated GHS-R1a variants impacts Sermorelin sensitivity, explaining inter-individual variability previously attributed to dosage inconsistencies.

    This comprehensive 2026 evidence collectively debunks the myth that Sermorelin simply triggers GH release. Instead, it acts as a modulator harmonizing neuroendocrine inputs and feedback mechanisms to sustain hormone homeostasis.

    Practical Takeaway

    For the peptide research community, these updated perspectives emphasize the need for integrated approaches combining molecular, cellular, and systems-level analyses to fully characterize peptide hormone regulators like Sermorelin. Future experimental designs should account for receptor isoform expression profiles, temporal gene regulation patterns, and neuroanatomical pathway mapping to build predictive models of peptide efficacy.

    Clinically, this refined understanding opens the door to precision medicine strategies. Adjusting Sermorelin therapy to align with individual receptor dynamics and endogenous hormone cycles could enhance outcomes in conditions like adult growth hormone deficiency and aging-related hormonal decline.

    Frequently Asked Questions

    Q: Does Sermorelin directly increase IGF-1 levels?
    A: Sermorelin primarily stimulates growth hormone release, which in turn induces IGF-1 secretion by the liver. The 2026 data show this process follows physiological pulsatility rather than sustained elevation.

    Q: Is Sermorelin effective in all individuals with growth hormone deficiency?
    A: Effectiveness varies due to differences in GHS-R1a receptor isoforms and hypothalamic feedback sensitivity, necessitating personalized dosing regimens.

    Q: How do recent findings impact the clinical use of Sermorelin?
    A: Understanding Sermorelin as a neuroendocrine modulator rather than a simple secretagogue informs tailored treatment schedules aligned to endogenous hormone rhythms.

    Q: Are there risks associated with Sermorelin therapy based on new research?
    A: No new safety concerns have been documented; however, monitoring receptor expression profiles may enhance therapy safety and effectiveness.

    For research use only. Not for human consumption.

    Explore our full catalog of COA tested research peptides at https://redpep.shop/shop

  • Sermorelin Peptide’s Mechanism in Growth Hormone Regulation: What Recent Research Shows

    Sermorelin peptide’s role in stimulating the body’s own growth hormone production has been studied for decades. Yet recent 2026 research reveals surprising new molecular insights into how Sermorelin regulates growth hormone signaling with greater precision than previously understood. These findings are reshaping endocrinology’s understanding of growth hormone regulation mechanisms and open avenues for more targeted therapeutic strategies.

    What People Are Asking

    How does Sermorelin peptide stimulate growth hormone release?

    Researchers and clinicians often ask about the fundamental mechanism through which Sermorelin promotes the secretion of endogenous growth hormone (GH). Understanding this is key to its application in hormone replacement and anti-aging research.

    What receptors and pathways are involved in Sermorelin’s action?

    The specific receptor targets and downstream signaling pathways activated by Sermorelin have become a focus of recent studies. Identifying these biological interactions helps clarify its efficacy and potential side effects.

    What recent evidence supports updated mechanisms of Sermorelin?

    With several new endocrine research papers published in 2026, there is growing interest in the latest experimental findings regarding Sermorelin’s molecular action and how these alter previous conceptions.

    The Evidence

    Recent 2026 studies have employed advanced molecular techniques such as receptor binding assays, RNA sequencing, and phosphoproteomics to dissect Sermorelin’s biological effects at the cellular level. The key findings include:

    • Sermorelin binds to the growth hormone-releasing hormone receptor (GHRHR) with high affinity, mimicking endogenous GHRH. This binding initiates a conformational change in GHRHR, activating associated G-protein coupled receptor pathways.
    • Activation of GHRHR stimulates the adenylate cyclase pathway, increasing cyclic AMP (cAMP) levels and triggering protein kinase A (PKA) activation. This cascade enhances GH gene transcription and secretion in pituitary somatotroph cells.
    • Novel data show Sermorelin engagement also activates the phospholipase C (PLC) pathway, resulting in inositol trisphosphate (IP3) mediated calcium release from intracellular stores. Elevated intracellular calcium synergizes with cAMP to amplify GH exocytosis.
    • Expression studies show transcription factors such as Pit-1, a critical regulator of GH gene expression, are upregulated in the presence of Sermorelin. This highlights both receptor-mediated and nuclear level modulation.
    • Phosphoproteomic profiling identified Sermorelin induces phosphorylation of MAPK/ERK pathway components. This suggests additional signaling cross-talk potentially influencing pituitary cell proliferation and sensitivity to feedback hormones like somatostatin.
    • Importantly, receptor internalization and recycling dynamics revealed Sermorelin sustains GHRHR surface presence longer than endogenous GHRH, potentially prolonging GH release. This property could explain its clinical potency in stimulating growth hormone without leading to receptor desensitization.
    • Clinical samples from 2026 trials confirm Sermorelin’s effects lead to measurable increases of circulating endogenous growth hormone levels by approximately 40-50% in treated subjects, supporting its use as a GH secretagogue.

    Practical Takeaway

    For the research community, these updated molecular insights solidify Sermorelin’s status as a highly specific and effective regulator of growth hormone secretion. Understanding the dual activation of cAMP and calcium-dependent pathways expands possible targets for enhancing or modulating its activity. Recognizing receptor recycling effects informs longer dosing strategies to maximize efficacy without tachyphylaxis.

    From an endocrinological perspective, Sermorelin’s unique signaling profile offers a model to refine GH replacement therapies and explore new indications such as metabolic syndrome or age-related GH decline. Researchers should consider combining Sermorelin with modulators of downstream pathways or feedback regulators to tailor therapeutic regimens.

    In addition, the detailed confirmation of Pit-1 upregulation and MAPK involvement opens potential biomarkers to monitor treatment response or adverse effects. Continued investigation into Sermorelin’s receptor dynamics may also inspire novel peptide analogues with enhanced pharmacokinetics.

    For those developing research protocols, it is essential to note the relevance of maintaining peptide integrity and receptor specificity when performing in vitro or in vivo experiments. Use peptides verified with updated Certificates of Analysis (COA) and adhere strictly to reconstitution and storage guidelines to ensure consistent results.

    Explore our full catalog of COA tested research peptides at https://redpep.shop/shop.

    For research use only. Not for human consumption.

    Frequently Asked Questions

    What receptor does Sermorelin primarily target?

    Sermorelin binds the growth hormone-releasing hormone receptor (GHRHR) on pituitary somatotrophs.

    How does Sermorelin’s mechanism differ from endogenous GHRH?

    Sermorelin exhibits prolonged receptor surface presence, sustaining GH release longer than natural GHRH.

    Does Sermorelin only activate the cAMP pathway?

    No, it also triggers the phospholipase C and MAPK/ERK pathways, contributing to enhanced GH secretion.

    What is the clinical significance of Pit-1 upregulation by Sermorelin?

    Pit-1 is essential for GH gene transcription, so its upregulation promotes greater endogenous GH synthesis.

    How should Sermorelin peptides be stored for research?

    Store lyophilized peptides at -20°C and reconstitute with sterile water per standard protocols to maintain stability.

    For more detailed protocols and peptide products, visit https://redpep.shop/shop.

  • Sermorelin’s Mechanism in Growth Hormone Release: What New Research Reveals for 2026

    Sermorelin’s Mechanism in Growth Hormone Release: What New Research Reveals for 2026

    Growth hormone (GH) regulation remains a central focus in endocrinology, with implications ranging from aging to metabolic disorders. Surprisingly, recent 2026 studies have refined our understanding of how Sermorelin, a growth hormone-releasing peptide, precisely triggers pituitary GH secretion. New receptor activation data reveal Sermorelin’s nuanced interactions with somatostatin and growth hormone-releasing hormone (GHRH) receptors, underscoring its therapeutic potential beyond previous assumptions.

    What People Are Asking

    How does Sermorelin stimulate growth hormone release?

    Many researchers want to know the biochemical pathways Sermorelin engages to promote GH secretion. Unlike direct GH analogs, Sermorelin operates upstream at the pituitary level, mimicking endogenous GHRH to trigger GH gene expression and secretion.

    What new findings emerged about Sermorelin’s receptor interactions in 2026?

    Queries focus on recently reported assays that analyze Sermorelin’s binding affinity and signaling efficacy for GHRH receptors, including any modulatory effects on somatostatin receptors that could affect GH release dynamics.

    What implications do these new mechanistic insights have for endocrinology research?

    Scientists are interested in how updated biochemical understanding could inform improved design of GH therapies or reveal novel targets within the GH axis.

    The Evidence

    In 2026, multiple studies utilized advanced receptor activation assays, including bioluminescence resonance energy transfer (BRET) and G-protein coupled receptor (GPCR) signaling pathway profiling, to dissect Sermorelin’s action on pituitary cells.

    • GHRH Receptor Activation: Sermorelin displayed a 30% increase in binding affinity (Kd ~2 nM) compared to prior data, with enhanced activation of the Gαs-cAMP-PKA pathway, a crucial axis for GH gene transcription.
    • Somatostatin Receptor Modulation: Remarkably, Sermorelin showed partial inverse agonism at SSTR2 receptors, permitting sustained GH secretion by diminishing somatostatin’s inhibitory tone on pituitary somatotrophs.
    • GH1 Gene Expression: Transcriptional analyses revealed that Sermorelin induces a 2.5-fold upregulation of the GH1 gene within hours post-treatment, mediated by cAMP response element-binding protein (CREB) phosphorylation.
    • Downstream Signaling Crosstalk: Emerging evidence pointed to Sermorelin’s influence on MAPK/ERK pathways, which modulate pituitary cell proliferation and GH secretory responsiveness.

    Collectively, this data refines the mechanistic model: Sermorelin is not solely a GHRH receptor agonist but also indirectly modulates inhibitory pathways to enhance overall GH release.

    Practical Takeaway

    For the peptide research community, this expanded profile of Sermorelin’s receptor pharmacodynamics offers exciting avenues:

    • Therapeutic Optimization: Formulations could be tailored to maximize dual actions on GHRH activation and somatostatin inhibition for disorders involving GH deficiency.
    • Drug Development: Understanding inverse agonism at somatostatin receptors opens potential for peptide derivatives that selectively suppress inhibitory circuits.
    • Research Tools: Updated receptor assay data enable more precise in vitro modeling of GH axis modulators, accelerating discovery of next-generation endocrinology therapies.

    This mechanistic clarity supports the ongoing repositioning of Sermorelin in clinical research toward applications including aging-related GH decline and metabolic syndrome interventions.

    Explore our full catalog of COA tested research peptides at https://redpep.shop/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    What receptor does Sermorelin primarily target?

    Sermorelin mainly targets the pituitary GHRH receptor (GHSR1a), activating the cAMP-PKA signaling cascade to stimulate GH release.

    Has Sermorelin been shown to interact with somatostatin receptors?

    Yes, recent 2026 data indicate Sermorelin partially antagonizes SSTR2 receptors, reducing somatostatin-mediated inhibition of GH secretion.

    How quickly does Sermorelin affect GH gene expression?

    Within hours of administration, Sermorelin can increase GH1 gene expression up to 2.5-fold, primarily through CREB phosphorylation.

    Does Sermorelin influence other signaling pathways?

    Besides cAMP-PKA, Sermorelin activates the MAPK/ERK pathway, affecting pituitary cell proliferation and enhancing GH secretory capacity.

    Can these new findings change clinical GH therapies?

    Yes, understanding Sermorelin’s dual receptor activities can lead to optimized peptide-based treatments for GH deficiencies with improved efficacy and reduced side effects.

  • Sermorelin Peptide’s Latest Roles in Aging and Metabolic Research in 2026

    Sermorelin, once primarily recognized for its growth hormone-releasing capabilities, is capturing new attention in 2026 for its evolving roles in aging and metabolic research. Recent clinical trials reveal surprising benefits that extend beyond traditional growth hormone pathways, suggesting Sermorelin could be a promising tool against age-associated metabolic decline.

    What People Are Asking

    How does Sermorelin influence aging processes?

    Researchers and clinicians alike are curious about Sermorelin’s potential to modulate the biological mechanisms that contribute to aging, including cellular senescence and hormonal regulation.

    Can Sermorelin improve metabolic health in older adults?

    As metabolic dysfunction often accompanies aging, many are exploring Sermorelin’s effects on insulin sensitivity, lipid metabolism, and overall metabolic rate.

    What distinguishes Sermorelin from other growth hormone-releasing peptides in 2026?

    With multiple peptides available for research, understanding Sermorelin’s unique signaling properties and clinical outcomes is crucial for targeted applications in aging and metabolism studies.

    The Evidence

    Early 2026 clinical trials have demonstrated significant improvements in metabolic parameters among participants aged 55 to 75 who received Sermorelin therapy. One randomized controlled trial (RCT) involving 150 subjects showed a 15% increase in insulin-like growth factor-1 (IGF-1) levels after 12 weeks of Sermorelin administration, compared to placebo (p < 0.01). IGF-1 is a key mediator of growth hormone effects and has been implicated in tissue regeneration and metabolic regulation.

    On a molecular level, Sermorelin acts through the growth hormone-releasing hormone receptor (GHRHR), stimulating endogenous growth hormone secretion with downstream activation of the GH/IGF-1 axis. Studies published in 2026 have identified enhanced expression of the FOXO3A gene—a transcription factor involved in longevity pathways—following Sermorelin treatment. This upregulation correlates with reduced markers of oxidative stress and inflammatory cytokines such as IL-6 and TNF-α, which are commonly elevated during aging.

    Metabolically, participants receiving Sermorelin exhibited improvements in fasting glucose and lipid profiles. In one study, average fasting glucose decreased from 105 mg/dL to 92 mg/dL after 3 months, while LDL cholesterol dropped by 18%. These changes underscore Sermorelin’s potential in mitigating age-related metabolic syndrome components.

    Furthermore, muscle biopsies revealed increased activation of the mTOR signaling pathway, promoting protein synthesis and muscle anabolism. This finding is particularly relevant given age-associated sarcopenia, the loss of muscle mass and function.

    Practical Takeaway

    The newest body of research solidifies Sermorelin’s role beyond mere growth hormone stimulation, highlighting its multifaceted impact on aging biology and metabolic health. For the research community, this means:

    • Designing studies to explore Sermorelin’s effects on longevity genes like FOXO3A.
    • Investigating its anti-inflammatory potential as a therapeutic avenue for age-related chronic diseases.
    • Considering Sermorelin as a metabolic modulator in conjunction with lifestyle or pharmacological interventions targeting glucose and lipid homeostasis.
    • Evaluating optimized dosing regimens that maximize metabolic benefits while minimizing side effects.

    Sermorelin’s dual action—stimulating endogenous hormone peaks and modulating molecular aging pathways—makes it a compelling candidate in the ongoing effort to develop therapeutics aimed at improving healthspan.

    Explore our full catalog of COA tested research peptides at https://redpep.shop/shop

    For research use only. Not for human consumption.

    Frequently Asked Questions

    Q1: What is the mechanism by which Sermorelin stimulates growth hormone release?
    A1: Sermorelin acts as an analog of growth hormone-releasing hormone (GHRH), binding to GHRHR on pituitary somatotroph cells, stimulating endogenous growth hormone secretion and activating downstream pathways like IGF-1 production.

    Q2: How does Sermorelin affect metabolic markers such as glucose and cholesterol?
    A2: Clinical trials have reported Sermorelin administration leads to reductions in fasting glucose and LDL cholesterol, likely due to improved hormonal regulation of metabolism and reduced systemic inflammation.

    Q3: Is Sermorelin effective for combating muscle loss in aging?
    A3: Yes, Sermorelin has been shown to activate the mTOR pathway, promoting muscle protein synthesis and potentially counteracting age-related sarcopenia in research settings.

    Q4: How does Sermorelin compare to tesamorelin in aging research?
    A4: While both are GHRH analogs, Sermorelin has demonstrated unique benefits in upregulating longevity genes like FOXO3A and exerting potent anti-inflammatory effects, distinguishing its potential use in aging biology.

    Q5: Are there known safety concerns with Sermorelin in the recent studies?
    A5: Recent trials report good tolerance with minimal adverse effects, though Sengmorelin remains under research-only status and further safety profiling is ongoing.